Results 11 to 20 of about 23,127 (334)
Indian Journal of Endocrinology and Metabolism, 2012 Nutrient excess results in systemic inflammation in diabetes contributing to insulin resistance, dyslipidaemia and increased cardiovascular risk. GLP-1 agonists and DPP-4 inhibitors, which are now well accepted therapies for diabetes may play a unique ...
Amitabh Hatwal
doaj +3 more sources
Pleiotropic effects of incretins
Indian Journal of Endocrinology and Metabolism, 2012 Drugs that augment the incretin system [glucagon like peptide (GLP) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] represent a novel class of anti-hyperglycemic agents that have shown to improve the health and survival of beta-cells (improvement
Vishal Gupta
doaj +3 more sources
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020 [PDF]
Endocrinology and Metabolism, 2021 Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives.
Eun-Jung Rhee +2 more
doaj +1 more source
Incretins (GLP1 r agonists and dual, triple agonists) and the liver.
Journal of Hepatology, 2023 The principle pathological drivers of metabolic dysfunction associated steatohepatitis (MASH) are obesity and associated insulin resistance, rendering them key therapeutic targets. As Glucagon-like Peptide 1 receptor agonists (GLP-1RA) have been licensed
P. Newsome, P. Ambery
semanticscholar +1 more source
Diabetologia, 2023 Glucagon-like peptide-1 receptor agonists (GLP-1RAs, incretin mimetics) and dipeptidyl peptidase-4 inhibitors (DPP-4is, incretin enhancers) are glucose-lowering therapies with proven cardiovascular safety, but their effect on microvascular disease is not
J. Goldney, J. Sargeant, M. Davies
semanticscholar +1 more source
Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
Medicina, 2022 The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and ...
Angelo Maria Patti +10 more
doaj +1 more source
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Pharmacological Reviews, 2008 Wook Kim, Josephine M Egan
exaly +2 more sources
The Role of Incretins on Insulin Function and Glucose Homeostasis
Endocrinology, 2021 The incretin effect—the amplification of insulin secretion after oral vs intravenous administration of glucose as a mean to improve glucose tolerance—was suspected even before insulin was discovered, and today we know that the effect is due to the ...
J. Holst, L. Gasbjerg, M. Rosenkilde
semanticscholar +1 more source
Incretin‐based therapies [PDF]
Journal of Diabetes, 2012 AbstractIncretin‐based therapies have established a foothold in the diabetes armamentarium through the introduction of oral dipeptidyl peptidase‐4 inhibitors and the injectable class, the glucagon‐like peptide‐1 receptor agonists. In 2009, the American Diabetes Association and European Association for the Study of Diabetes authored a revised consensus ...
Stonehouse, Anthony H +2 more
openaire +2 more sources
Gluco-incretins regulate beta-cell glucose competence by epigenetic silencing of Fxyd3 expression. [PDF]
, 2014 BACKGROUND/AIMS: Gluco-incretin hormones increase the glucose competence of pancreatic beta-cells by incompletely characterized mechanisms. METHODS: We searched for genes that were differentially expressed in islets from control and Glp1r-/-; Gipr ...
Chatton, J.Y. +7 more
core +9 more sources